Evidence map›Paper›PMID 41644295›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

A Phase 0 Imaging Trial of [

Stephen A Graves, David L Bushnell, Michael K Schultz, Sanchay Jain, Kellie L Bodeker, Yusuf Menda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen A GravesDepartment of Radiology, University of Iowa, Iowa City, Iowa.
David L BushnellDepartment of Radiology, University of Iowa, Iowa City, Iowa.
Michael K SchultzDepartment of Radiology, University of Iowa, Iowa City, Iowa.
Sanchay JainDepartment of Radiology, University of Iowa, Iowa City, Iowa.
Kellie L BodekerDepartment of Radiology, University of Iowa, Iowa City, Iowa.
Yusuf MendaDepartment of Radiology, University of Iowa, Iowa City, Iowa; yusuf-menda@uiowa.edu.

Funding

Project 4: New Approaches to Improving the Effectiveness of Radionuclide Targeted Treatments in Neuroendocrine TumorsP50CA174521 · NCI · UNIVERSITY OF IOWA · PI MENDA, YUSUF · 2015 to 2021
$13.2M
Project 3: GLP1R and GIPR Agonists in GEP NETs ProjectP50CA302572 · NCI · UNIVERSITY OF IOWA · PI JAMES R HOWE, Yusuf Menda · 2025 to 2026
$6.5M
Image-guided Diagnosis and Therapy of Neuroendocrine TumorsR01CA167632 · NCI · UNIVERSITY OF IOWA · PI MENDA, YUSUF, O'DORISIO, M. SUE · 2012 to 2016
$2.6M
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine TumorsR01CA243014 · NCI · UNIVERSITY OF IOWA · PI MENDA, YUSUF · 2019 to 2024
$2.5M
NCI NIH HHS P50 CA174521NCI NIH HHS P50 CA302572NCI NIH HHS R01 CA167632NCI NIH HHS R01 CA243014
6 · The paper itself

Abstract

Peptide receptor radionuclide therapy (PRRT) using α-particle emitters has potential to provide improved patient outcomes over those achieved with β-particle PRRT. A promising candidate radiopharmaceutical pair, PSC-PEG

Indexed as

Lead RadioisotopesNeuroendocrine TumorsOctreotideRadiotherapy Planning, Computer-AssistedAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisRadiometryRadiopharmaceuticalsReceptors, SomatostatinRecurrenceSingle Photon Emission Computed Tomography Computed TomographyLead-212Lead RadioisotopesOctreotideRadiopharmaceuticalsReceptors, Somatostatin[203Pb]Pb-VMT-α-NET[212Pb]Pb-VMT-α-NETneuroendocrine tumorsradiopharmaceutical therapyα-PRRT

Identifiers

PMID41644295
PMCPMC13041586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.